Novo Nordisk introduces HemaGo, a mobile application to track hemophilia treatment, bleeding episodes and life events

PRINCETON, N.J., Nov. 27, 2012 /PRNewswire/ -- Novo Nordisk announced today the introduction of HemaGo, a mobile application (app) to help individuals with hemophilia and their caregivers monitor the details of treatment, including medications, dosing, bleed information and the impact of hemophilia on life events.  

The app offers multiple profiles so that more than one family member can use the tool.  HemaGo helps them track multiple medications, set reminders for treatment or doctor's appointments.  As well, HemaGo can be used to record factor usage and reason for infusion; the type, location and duration of bleeding events; and pain scores, including the impact of the bleeding episode on the individual's participation in work or school. 

"For the first time, individuals can track virtually every aspect of living with a bleeding disorder, regardless of their medication or disorder," said Eddie Williams, Corporate Vice President, Biopharmaceuticals.  "Thanks to input from members in the hemophilia community, we've created a first in class offering that provides benefits to all hemophilia patients and healthcare professionals."

Information from the HemaGo app syncs to Novo Nordisk's Changing Possibilities in Hemophilia website (www.changingpossibilities-us.com).  At the site, individuals have access to comprehensive reporting features, including treatment logs, bleed logs, and quality of life reports.  This information may be shared with the individual's healthcare team, including their hemophilia treatment center and home healthcare company. 

Novo Nordisk does not have access to patient-specific information.  The company's access is restricted to generic information ("de-identified") in which the data has been stripped so that the individual source cannot be identified, in accordance with Health Insurance Portability and Accountability Act of 1996 (HIPAA) Privacy and Security Rules. 

Novo Nordisk is working with the American Thrombosis and Hemostasis Network (ATHN) to enable patients who choose the option to link their diary data with their other medical records on ATHN's national database of bleeding disorder treatment information. 

HemaGo was developed with the participation of Novo Nordisk's Consumer Council, which is comprised of bleeding disorder community members.

HemaGo is available for free download at www.changingpossibilities-us.com.  The Android version is expected to be available in November 2012.  The app's tools are also available from the website for individuals who do not have a mobile device.

Headquartered in Denmark, Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit novonordisk.com.

iPhone and iPad are registered trademarks of Apple Inc.

Android is a registered trademark of Google.

SOURCE Novo Nordisk